Jake Rossetto is a scientist by training and a biotech operator specializing at the intersection of scientific innovation and commercialization.

 

Currently, he is pursuing an MBA with a concentration in finance at Babson College, where he is formalizing his expertise in venture capital and corporate finance. This academic focus complements his technical background in biochemistry and biophysics, allowing him to integrate rigorous scientific analysis with the strategic financial frameworks required to scale high-growth life science organizations.

 

He previously worked on vaccine platform development at Affinivax, supporting the expansion of the company’s pipeline prior to its $3.2 billion acquisition by GSK. Jake was also an early team member at Atias Pharma, where he was instrumental in scientific positioning and crafting investor materials during the company’s fundraising efforts.

 

Beyond his operational roles, Jake serves as Managing Director for the Nucleate Boston Activator, leading the programming that evaluates and supports emerging biotech startups. In this capacity, he has reviewed hundreds of early-stage companies, guiding the selection and strategic development of new venture teams. He previously spearheaded community-building initiatives within the Boston life sciences ecosystem, including organizing Nucleate’s Annual Summit and establishing the Alumni Relations function to support founders post-acceleration.

 

At Atoll, Jake leverages this dual-domain expertise to bridge the gap between technical complexity and investment thesis. He helps clients translate breakthrough science into compelling investment narratives while providing investors with the rigorous technical due diligence and commercial mapping necessary to deploy capital with confidence.